Trials / Completed
CompletedNCT04131595
Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Bavarian Nordic · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in the 3 treatment groups receiving different doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MVA-BN-WEV Dose 1 | 1 x 10\^7 Inf.U MVA-BN-WEV vaccine |
| BIOLOGICAL | MVA-BN-WEV Dose 2 | 1 x 10\^8 Inf.U MVA-BN-WEV vaccine |
| BIOLOGICAL | MVA-BN-WEV Dose 3 | 2 x 10\^8 Inf.U MVA-BN-WEV vaccine. |
Timeline
- Start date
- 2019-10-07
- Primary completion
- 2020-07-22
- Completion
- 2020-07-22
- First posted
- 2019-10-18
- Last updated
- 2020-08-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04131595. Inclusion in this directory is not an endorsement.